This deal may help ALNY’s credibility, but it’s less consequential than it seems on first glance, IMO. MON has licensed RNAi IP from other companies (e.g. #msg-75363639) and MON was already using RNAi in its corn-rootworm trait, which is in phase-3 (#msg-70545277).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”